Efgartigimod
argenx
[]
catherine broome presented at #ash22 results from a phase 3 rct in itp. efgartigimod blocks the fcrn receptor and prevents ig recirculation. it is given iv every 1-2 weeks. efficacious in some patients. #itp 1/3 
Professor of Haemostasis and Thrombosis in Sheffield, UK. I tweet about thrombosis, hemophilia, COVID-19, medicine & NHS. Opinions are my own.